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Efficacy and Safety of Drug Eluting Stents in the Real World: 8 Year Follow Up
Denise Pellegrini
Hospital São Lucas PUC, Porto Alegre, Brazil
Introduction: Drug eluting stents have been used in daily practice since 2002, with clear
advantage in reducing the risk of target vessel revascularization, with the impressive
reduction of 50% to 70% in restenosis rate. However, the occurrence of late thrombosis
could compromise results in the long term, especially if the risk of this eventwere sustained
over the years. In this context, the registry of clinical practice gains special value.
Objective: Evaluation of efﬁcacy and safety of drug-eluting stents in the real world.
Methods: We report the ﬁndings of all patients that underwent percutaneous coro-
nary intervention with a drug eluting stent in the period from January 2002 to April
2007, and followed up for 8 years. Drug eluting stents were used in accordance with
the clinical and interventional cardiologist decision and availability of the stent.
Results: A total of 611 patients were included, with clinical follow-up obtained for
96.2% up to 8 years. Total mortality was 8,7%. Non-fatal infarction occurred in 4.3 %
of the cases. Target vessel revascularization was 12.4% and the target lesion revascu-
larization 8%. The rate of stent thrombosis was 2.1%. There were no new episodes of
stent thrombosis after the ﬁfth year of follow-up. Comparative subanalysis showed no
outcome differences between the stents Cypher, Taxus and Endeavor.
Conclusion: These ﬁndings indicate that drug eluting stents remain safe and effective
at very long term follow-up. Patients in the “real world” may beneﬁt from drug eluting
stenting with excellent results in the long-term.
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Aims: We evaluated the, feasibility and the acute performance of the bioresorbable
vascular scaffolds (BVS) for treatment of patients presenting with ST-segment
elevation myocardial infarction (STEMI).
Methods and Results: The present investigation is a prospective, single-arm, single-
centre study, reporting data after BVS implantation in STEMI patients. Quantitative
coronary angiography and optical coherence tomography (OCT) data were evaluated.
Clinical outcomes are reported at 6 months follow-up. The intent-to-treat population
comprises a total of 49 patients. The procedural success was 97.9%. Pre-procedure
TIMI-ﬂow was 0 in 50.0% of the patients; after BVS implantation a TIMI-ﬂow III
was achieved in 91.7% of patients and the post-procedure percentage diameter stenosis
was 14.7  8.2%. No patients had angiographically visible residual thrombus at the
end of the procedure. OCT analysis performed in 31 patients, showing that the mean
lumen area was 8.021.92 mm2, minimum lumen area 5.951.61 mm2, mean
incomplete scaffold apposition area 0.1180.162 mm2, mean intraluminal defect area
0.0130.017 mm2, mean percentage malapposed struts per patient 2.803.90%.
Scaffolds with >5% malapposed struts were 7. Six months follow-up will be available
in Feb 2014.
Conclusion: a. : In the present series the BVS implantation in patients presenting
with acute myocardial infarction appeared feasible, with high rate of ﬁnal TIMI-ﬂowIII and good acute scaffold apposition on OCT. Medium term follow-up data will be
presented at CRT.Renal Denervation
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Arterial Stiffness as an Early Marker of Renal Sympathetic Denervation Effectiveness
Andrius Berukstis,1 Nerijus Misonis,1 Ligita Ryliskyte,1 Rokas Navickas,1
Kamile Cerlinskaite,2 Aleksandras Laucevicius1
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Background: Renal sympathetic denervation (RSD) has been reported to reduce
blood pressure in patients with resistant arterial hypertension, although it takes time
before noticeable changes after the procedure occur. There are several reports on late
changes in arterial stiffness after RSD. We have investigated early and late changes in
arterial stiffness after denervation searching for the markers of RSD effectiveness.
Methods: We have evaluated 20 patients with resistant arterial hypertension (age
56.27.4 years, 11 male, 9 female, mean 24-hour ambulatory blood pressure (BP) -
160/9619/16 mm Hg, using 6.11.1 antihypertensive drugs), who underwent
bilateral RSD. Arterial stiffness parameters were measured before the procedure,
during the ﬁrst 48 hours after RSD and, subsequently, after 1, 3 and 6 months.
Results: During the ﬁrst 48 hours after RSD, a signiﬁcant reduction in peripheral BP
from 182/10728/19 to 163/9517/11 mmHg (p¼0.003), and mean arterial pressure
(MAP) from 13523 to 11613 mmHg (p¼0.0003) was observed. RSD signiﬁcantly
reduced carotid-femoral pulse wave velocity (PWV) during the ﬁrst 48 hours from
11.22.9 to 9.72.1 m/s (p¼0.0004) and carotid-radial PWV from 10.32.4 to
8.81.4 (p¼0.008). Analysis of variance revealed the MAP independent improvement
of PWV during 48 hours after RSD (r¼-0.07, p¼0.8). Furthermore, a substantial
decrease in carotid-femoral PWV has been recorded at 1, 3 and 6 months, 9.52.3
(p<0.001), 9.412.78 (p¼0.006) and 8.942.03 (p<0.001), respectively. In addition,
reduction in carotid-radial PWV sustained at 1, 3 and 6 months, 9.241.33
(p¼0.051), 8.991.65 (p¼0.063) and 8.671.20 (p¼0.007), respectively.
Conclusion: Changes in arterial stiffness occur early after RSD. During the ﬁrst 48
hours after the procedure, a signiﬁcant reduction of arterial stiffness parameters, which
remained at 1, 3 and 6 months have been noted. RSD effects on PWV were inde-
pendent from blood pressure changes.
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Renal Denervation with a Percutaneous Bipolar Radiofrequency Balloon Catheter in
Patients with Resistant Hypertension: Efficacy and Safety Results From the
REDUCE-HTN Trial
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Background: The Vessix Renal Denervation System (Boston Scientiﬁc, Natick, MA)
consists of a radiofrequency generator and a balloon catheter mounted with a bipolar
radiofrequency electrode array. The objective of the REDUCE-HTN Clinical Study is
to evaluate the performance of the Vessix System in treating medication-resistant
hypertension.
